Official executive summary of the report of the WHO Expert Working Group on Research and Development FinancingSubmitted by thiru on 23. December 2009 - 13:54
23 December 2009
The Official Executive Summary and Recommendations of the Report of the Expert Working Group on Research and Development Financing to the Executive Board has been published on the website of the WHO Executive Board as document EB126/6 Add.1. It has a provisional agenda item number of 4.3. The official WHO link to this Executive Summary is: http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_6Add1-en.pdf
On Saturday, KEI filed comments with the WHO EWG's 2nd web based hearing. Our comments focused on the criteria for new proposals.
Friday, 09 November 2007
KEI comments to IGWG2
8 November 2007
KEI appreciates the opportunity to speak today. Our comments will focus on 3 items.
Wednesday, 23 May 2007
Informe de KEI
November 9, 2007. Malini Aisola. Reasons Why the IGWG Should Not Place Limits on the Scope of Disease.
At the WIPO Conference on Intellectual Property and Public Policy Issues today, Margaret Chan, the Director General of the World Health Organization, made the following speech at WIPO’s Conference on Intellectual Property and Public Policy Issues on the topic of “Strengthening Multilateral Cooperation on IP and Public Health” where she shared the limelight with Pascal Lamy, Director General of the World Trade Organ
The World Health Organization just published a report on this week’s second meeting of the WHO Expert Working Group (EWG) on R&D Financing.
Today nine NGOs sent a letter the WHO Expert Working Group on R&D Financing. The letter focuses on issues about transparency, conflicts of interest, and EWG outcomes. The whole EWG seems to be going very badly right now, in part because of the US government and much of Northern Europe is working hand and glove with the pharmaceutical industry, and partly because the Gates Foundation is protecting big pharma and seems to have an ideological attachment to strong IPR.